ADAMICHOU CHRISTINA ET AL: "Cytokine targets in lupus nephritis: Current and future prospects", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 206, 2 September 2018 (2018-09-02), pages 42 - 52, XP085806749, ISSN: 1521-6616, [retrieved on 20180902], DOI: 10.1016/J.CLIM.2018.08.013 (B1)

ASTROZENECA ET AL: "Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis - NCT02547922", CLINICALTRIALS.GOV, 14 September 2015 (2015-09-14), XP055946462, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/study/NCT02547922?term=NCT02547922&draw=2&rank=1> [retrieved on 20220726] (B1)

ASTROZENECA: "Protocol number: D3461C00007 A Multicentre, Randomised, Double-blind, Placebo controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis NCT02547922", 13 December 2017 (2017-12-13), XP055946495, Retrieved from the Internet <URL:https://s3.amazonaws.com/ctr-med-7111/D3461C00007/91395ece-af3d-4a03-b57b-c464aaf45d6a/ec5177ae-d50c-4d39-8857-0b696733664f/PXL_221659_D3461C00007_protocol_Redacted_FINAL-v1.pdf> [retrieved on 20220726] (B1)

CN-A- 113 527 490 (B1)

CN-A- 113 621 063 (B1)

WO-A1-2017/031288 (B1)

JAYNE DAVID ET AL: "Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis", ANNALS OF THE RHEUMATIC DISEASES, vol. 81, no. 4, 10 February 2022 (2022-02-10), GB, pages 496 - 506, XP055946470, ISSN: 0003-4967, Retrieved from the Internet <URL:https://ard.bmj.com/content/annrheumdis/81/4/496.full.pdf> DOI: 10.1136/annrheumdis-2021-221478 (B1)

MONTIGNY PAULINE M ET AL: "New Treatment Options in Lupus Nephritis", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, BIRKHAEUSER VERLAG AG, CH, vol. 70, no. 1, 17 March 2022 (2022-03-17), XP037724823, ISSN: 0004-069X, [retrieved on 20220317], DOI: 10.1007/S00005-022-00647-8 (B1)

TUMMALA RAJ ET AL: "Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers", LUPUS SCIENCE & MEDICINE, vol. 5, no. 1, 1 March 2018 (2018-03-01), pages e000252, XP055935289, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890854/pdf/lupus-2017-000252.pdf> DOI: 10.1136/lupus-2017-000252 (B1)

WO-A1-2013/188494 (B1)

JAYNE D. ET AL: "POS0690?RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS", ANNALS OF THE RHEUMATIC DISEASES, vol. 80, no. Suppl 1, 19 May 2021 (2021-05-19), GB, pages 592.1 - 592, XP055946862, ISSN: 0003-4967, Retrieved from the Internet <URL:https://ard.bmj.com/content/annrheumdis/80/Suppl_1/592.1.full.pdf> DOI: 10.1136/annrheumdis-2021-eular.1605 (B1)